Azeliragon
- Generic Name
- Azeliragon
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H38ClN3O2
- CAS Number
- 603148-36-3
- Unique Ingredient Identifier
- LPU25F15UQ
- Background
Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELLIRAGON TO TREAT BRAIN METASTASIS FROM BREAST CANCER
Cantex Pharmaceuticals received FDA Orphan Drug Designation for azeliragon to treat brain metastasis from breast cancer, adding to its designations for pancreatic cancer and glioblastoma. Azeliragon, an oral RAGE inhibitor, aims to address therapeutic challenges in aggressive breast cancer subtypes.
Cantex Scores Third FDA Orphan Drug Win for Breakthrough Breast Cancer Brain
Cantex Pharmaceuticals' azeliragon receives FDA Orphan Drug Designation for treating brain metastasis from breast cancer, adding to its designations for pancreatic cancer and glioblastoma. Azeliragon, an oral RAGE inhibitor, aims to address therapeutic challenges in aggressive breast cancer subtypes.
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ...
Cantex Pharmaceuticals' azeliragon receives FDA Orphan Drug Designation for treating brain metastasis from breast cancer, adding to its designations for pancreatic cancer and glioblastoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath